Allogene Therapeutics, Inc. (ALLO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Allogene Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Allogene Therapeutics, Inc. (ALLO) has returned 78.10% so far this year and 67.12% over the past 12 months.

Based on dividend-adjusted daily data since Oct 11, 2018, ALLO's average daily return is 0.00%, while the average monthly return is -0.73%.

Historically, 40% of months were positive and 60% were negative. The best month was May 2020 with a return of +66.6%, while the worst month was Apr 2024 at -38.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ALLO closed higher 47% of trading days. The best single day was Feb 14, 2025 with a return of +44.7%, while the worst single day was Oct 8, 2021 at -46.1%.

Allogene Therapeutics, Inc. has an annualized alpha of -17.33%, beta of 1.30, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since October 12, 2018.

• This stock participated in 153.33% of S&P 500 Index downside but only 6.67% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ALLO ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Allogene Therapeutics, Inc. (ALLO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Allogene Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Allogene Therapeutics, Inc. was 98.24%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current Allogene Therapeutics, Inc. drawdown is 95.48%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Allogene Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Allogene Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.